Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Shares Climb 6.25 Percent on Strong Q2 Revenue Growth

NEW YORK, Aug. 5 (GenomeWeb News) - Shares in Accelrys were up 6.25 percent, or $.33, at $5.61 in mid-afternoon trading after the company reported a 31-percent increase in second-quarter revenue and a narrowed net loss.


As  GenomeWeb News reported, total revenues for the period ended June 30 increased to $18.6 million from $14.2 million during the same period last year. This quarter's revenues included deferred revenue from the company's switch to subscription accounting.


Product development costs increased to $4.9 million, up from $4.1 million during the year-ago quarter.


Accelrys' net loss fell 40 percent to $3.7 million, or $.14 per share, from $6.2 million, or $.25 per share, for the second quarter of last year. Last year's loss included $1.1 million from discontinued operations.


As of June 30, Acclerys had $56.3 million in cash, restricted cash, cash equivalents, and marketable securities.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.